Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy

We recently demonstrated that simultaneous targeting of CD137 co-stimulatory and programmed cell death 1 (PD-1) co-inhibitory molecules synergistically induced an anticancer immune response in the ID8 syngeneic orthotopic mouse ovarian carcinoma model. We further showed that the therapeutic efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Huafeng, Zhao, Likun, Hellstrom, Ingegerd, Hellstrom, Karl Erik, Guo, Yajun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063147/
https://www.ncbi.nlm.nih.gov/pubmed/25050196
http://dx.doi.org/10.4161/onci.28248
_version_ 1782321755264647168
author Wei, Huafeng
Zhao, Likun
Hellstrom, Ingegerd
Hellstrom, Karl Erik
Guo, Yajun
author_facet Wei, Huafeng
Zhao, Likun
Hellstrom, Ingegerd
Hellstrom, Karl Erik
Guo, Yajun
author_sort Wei, Huafeng
collection PubMed
description We recently demonstrated that simultaneous targeting of CD137 co-stimulatory and programmed cell death 1 (PD-1) co-inhibitory molecules synergistically induced an anticancer immune response in the ID8 syngeneic orthotopic mouse ovarian carcinoma model. We further showed that the therapeutic efficacy was enhanced by treatment with cisplatin. These findings provide a rationale for evaluating dual targeting of CD137/PD-1 co-signaling molecules in ovarian cancer patients.
format Online
Article
Text
id pubmed-4063147
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40631472015-03-28 Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy Wei, Huafeng Zhao, Likun Hellstrom, Ingegerd Hellstrom, Karl Erik Guo, Yajun Oncoimmunology Author's View We recently demonstrated that simultaneous targeting of CD137 co-stimulatory and programmed cell death 1 (PD-1) co-inhibitory molecules synergistically induced an anticancer immune response in the ID8 syngeneic orthotopic mouse ovarian carcinoma model. We further showed that the therapeutic efficacy was enhanced by treatment with cisplatin. These findings provide a rationale for evaluating dual targeting of CD137/PD-1 co-signaling molecules in ovarian cancer patients. Landes Bioscience 2014-03-28 /pmc/articles/PMC4063147/ /pubmed/25050196 http://dx.doi.org/10.4161/onci.28248 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Wei, Huafeng
Zhao, Likun
Hellstrom, Ingegerd
Hellstrom, Karl Erik
Guo, Yajun
Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
title Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
title_full Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
title_fullStr Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
title_full_unstemmed Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
title_short Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
title_sort dual targeting of cd137 co-stimulatory and pd-1 co-inhibitory molecules for ovarian cancer immunotherapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063147/
https://www.ncbi.nlm.nih.gov/pubmed/25050196
http://dx.doi.org/10.4161/onci.28248
work_keys_str_mv AT weihuafeng dualtargetingofcd137costimulatoryandpd1coinhibitorymoleculesforovariancancerimmunotherapy
AT zhaolikun dualtargetingofcd137costimulatoryandpd1coinhibitorymoleculesforovariancancerimmunotherapy
AT hellstromingegerd dualtargetingofcd137costimulatoryandpd1coinhibitorymoleculesforovariancancerimmunotherapy
AT hellstromkarlerik dualtargetingofcd137costimulatoryandpd1coinhibitorymoleculesforovariancancerimmunotherapy
AT guoyajun dualtargetingofcd137costimulatoryandpd1coinhibitorymoleculesforovariancancerimmunotherapy

Ejemplares similares